Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Primary Target | Pathway | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|---|---|
| BT-20 | Tivantinib | 0.0031623 | MET | RTK | 1.0591 | 0.00314 |
| BT-20 | Tivantinib | 0.01 | MET | RTK | 1.0513 | -0.00049 |
| BT-20 | Abemaciclib | 10.0 | CDK4/6 | Cell cycle | -0.2160 | 0.37259 |
| BT-20 | Abemaciclib | 0.01 | CDK4/6 | Cell cycle | 0.7022 | -0.00034 |
| BT-20 | Taselisib | 1.0 | PI3Ka, g, d | PI3K/mTOR | -0.0196 | 0.26438 |
| BT-20 | Abemaciclib | 0.31623 | CDK4/6 | Cell cycle | 0.2635 | 0.00452 |
| BT-20 | Abemaciclib | 1.0 | CDK4/6 | Cell cycle | 0.2233 | 0.00560 |
| BT-20 | Cediranib | 1.0 | VEGFR/cKIT | RTK | 0.9874 | 0.01373 |
| BT-20 | Abemaciclib | 0.1 | CDK4/6 | Cell cycle | 0.3565 | 0.00950 |
| BT-20 | Cabozantinib | 1.0 | VEGFR2/MET | RTK | 1.0886 | -0.00310 |